One of the main side effects of cannabis legalization will hopefully be a better public understanding of how cannabis works with the human body and how using cannabinoids for pain management could be an alternative to current solutions.

Cannabinoid use for pain relief is not a new concept, but in recent years we’ve seen an explosion in the development of new methods for using cannabinoids in ways to more effectively treat pain while limiting psychoactive effects on cognitive function. The general public has taken notice and the stigma associated with taking medical cannabis is rapidly dissipating as more people see cannabis as a desperately needed alternative to opioid medications.

Today, cannabinoid based medicine is being utilized by a wide range of people from pro athletes for injuries and soreness to the general public for any number of other painful conditions and ailments.

Cannabinoids and the endocannabinoid system

Put very simply, the endocannabinoid system manages a number of important functions for the human body including pain-sensation, memory, mood and much more. It’s also the system that allows cannabinoids to do their thing. It does this through a series of cannabinoid receptors found throughout the brain and nervous system known as CB1 and CB2 receptors. The body naturally produces chemical compounds known as endocannabinoids that react with these receptors to maintain homeostasis, a state of internal hormonal balance to counteract the fluctuating conditions of the external environment.


What you need to know about Tesla's Battery Day

Expert Analysis of Tesla's Battery Day and the impact on Battery Metals Investing.

The endocannabinoid system also receives external cannabinoids found in the cannabis plant, such as cannabidiol (CBD) and tetrahydrocannabinol (THC). This is what gives cannabinoids their therapeutic potential. Since the endocannabinoid system controls biological responses like pain, nausea, muscle relaxation/inflammation and more, external cannabinoids can be used to stimulate this system and treat imbalances.

Of the hundreds of cannabinoids that have been identified, the best known and understood are CBD and THC. These two cousins react with the endocannabinoid system in very different ways. The main functional difference between the two is that THC binds with both the CB1 and CB2 receptors while CBD does not bind with CB1 receptors. CB1 receptors are mostly found in the brain, which is why THC has that characteristic psychoactive effect that we associate with cannabis. CBD, on the other hand, interacts with receptors indirectly, affecting the way other compounds interact with the receptors and increasing the body’s production of naturally-produced endocannabinoids.

Nearly a century of prohibition has kept cannabinoids out of the hands of researchers and set back our understanding of the therapeutic potential of cannabinoids dramatically, but the growing body of evidence supports cannabinoids as a viable treatment for pain.

Using cannabinoids for pain management goes mainstream

With more jurisdictions legalizing and creating new legal cannabis markets, the global market for medical cannabis products is growing rapidly. According to a November 2018 report by Research and Markets the global medical cannabis market is projected to hit $37 billion in 2023, up from $11 billion in 2017. That’s a staggering 22 percent compound annual growth rate over seven years. Because the needs of medical users differ greatly from the preferences of recreational users major cannabis producers like Aurora Cannabis (TSX:ACB) and smaller players are investing millions into new and innovative medical products in order to meet the increasing demand from consumers seeking an alternative to opioid-based pain relief.

The world of professional sport has provided an arena for using cannabinoids for pain management and relief. So far these developments have focused mainly, but not exclusively, on CBD medicine, though athletes have been using THC for pain relief in unofficial capacities for some time. Studies and anecdotal evidence show the CBD’s anti-inflammatory properties could make it a useful tool for athletes looking for relief from soreness, muscle and joint damage or injuries that won’t affect physical or cognitive performance like many opioid medications or THC-rich cannabis.

UFC mixed martial artist Nick Diaz was famously seen vaping CBD oil during his post-match press conference after his 2016 loss to Conor McGregor. Diaz explained to the press that the oil was for post-fight muscle inflammation. The event caused controversy in the sport world at the time, but CBD was removed from the International Olympic Committee sanctioned anti-doping agency’s list of banned substances less than a year later. Other athletes including NFL linebacker Derrick Morgan and former tackle Eugene Monroe have also gone public with their use of CBD to treat sport-related ailments.

Cannabis pain relief players

The growth of the medical cannabis market has caused the emergence of a number of CBD players. NanoSphere Health Sciences (CSE:NSHS) is one such company. NanoSphere has been working on developing transdermal technology that improves the bioavailability of cannabinoids as they move through the bloodstream. The company’s Evolve Formulas Transdermal NanoSerum™ CBD utilizes a combination formula of synergistic cannabinoids, with each precision-metered dose containing 15mg of CBD and 1.5mg of THC. According to NanoSphere, this ‘nano-particle delivery’ technology will allow for more accurate dosing, making cannabis products more viable prescription options for health professionals.

Phivida Holdings (CSE:VIDA) is another medical cannabis company developing products for pain relief. In addition to other offerings, Phivida has developed a line of protein shakes aimed at the sports-oriented market and infused with a proprietary CBD blend designed specifically to aid muscle and joint repair and relieve post-workout pain and inflammation. Matica Enterprises (CSE:MMJ,FWB:39N,OTC Pink:MQPXF) is developing a topical time-release THC/CBD cream that medical cannabis patients that can be used to manage for pain management along with other ailments.


The pain relief pharmaceutical market is in desperate need of non-opioid based non-addictive pain relief options, and cannabis based medicine is poised to fill that void. As medical cannabis legalisation continues to spread across North America, Europe and beyond, the opportunities for companies developing these solutions continue to expand. Meanwhile growing understanding and acceptance of cannabinoid medicine spurred by high profile use in the professional sports industry and elsewhere will continue to open minds within these markets.

This article was written according to INN editorial standards to educate investors.

 BioHarvest Sciences Inc. (CSE: BHSC) (the “Company” or “BioHarvest”) invites its shareholders and the general public to join a Live Video Conference (“Webinar”) on Thursday, January 21st, 2021 at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time). Ilan Sobel, CEO of BHSC, will host the event and discuss progress on Bioharvest’s Growth Plan, which will include highlights of the 2020 milestones achieved, key business capabilities built, and will provide an important overview of 2021 Priorities.

The presentation will be approximately 35 minutes, followed by a live question and answer session.

Keep reading... Show less

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”), reports that it has sold its 50% interest in Cobra Ventures Inc. (“Cobra”), which sale included all funds previously advanced by World Class to Cobra, to the remaining shareholder of Cobra, for $2,500,000 in cash

An investment group led by Richard Goldstein retains 100% control of Cobra, and its senior secured debenture of Hydrx Farms Ltd. (“Hydrx”), acquired by Cobra in October 2020.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Kurt Schmidt, President and Chief Executive Officer, will speak at the 24th Annual CIBC Western Institutional Investor Conference on Friday, January 22, 2021 at 4:10 p.m. EST.

A recording will be available on the Investors section of the Company’s website at .

Keep reading... Show less
  • Disease control of root-rot Aphanomyces zoospores in laboratory tests.
  • Outstanding Efficacy: 100% control at economic application rates within 24 hours.
  • Aphanomyces is a soil-borne root-rot disease that destroys peas, lentils, and legume crops.

MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce successful laboratory test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces”) via an independent third party facility: 100% control at economic application rates within 24 hours. MustGrow will now advance to larger scale greenhouse and field tests. Study results and applicability are patent-protected under MustGrow’s existing suite of issued patents.

MustGrow’s remarkably safe and effective organic biopesticide is plant-based – harnessing the mustard seed’s natural defense mechanism to control diseases, pests, and weeds with an organic food-grade biopesticide.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here:

Keep reading... Show less